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Background. Campylobacter species are one of the main causes of bacterial food poisoning worldwide. Recently, WHO reported
that the emergence of fluoroquinolone-resistant Campylobacter species is becoming a public health issue around the world. +e
aim of the present systematic review and meta-analysis was to evaluate the prevalence of the antimicrobial susceptibility patterns
of Campylobacter species, especially fluoroquinolone-resistant strains isolated from human and animal origins in Iran.Methods.
Using related keywords and without date and language limitations, a comprehensive literature search was conducted in PubMed,
Scopus, ISI Web of Knowledge, Google Scholar, and SID to identify relevant studies on the prevalence of the antimicrobial
susceptibility patterns of Campylobacter species in Iran. Results. A total of 34 reports (9 in Persian and 25 in English) were selected
based on inclusion and exclusion criteria. Disk diffusion, E-test, and agar dilution were common methods used for antimicrobial
susceptibility testing. +e antibiotic resistance profiles of Campylobacter species against fluoroquinolones were as follows: 53.6%,
41.8%, and 0% to ciprofloxacin for C. jejuni, C. coli, and C. lari, respectively, 24.3% and 25.1% to enrofloxacin for C. jejuni and
C. coli, respectively, 59.6% and 49.2% to nalidixic acid for C. jejuni and C. coli, respectively, and 87.3% and 64.7% to ofloxacin for
C. jejuni and C. coli, respectively. Conclusion. Our findings revealed a high prevalence of fluoroquinolone-resistant Campylobacter
species in Iran. +is calls for the use of more effective antibiotics with low resistance rates including aminoglycosides, chlor-
amphenicol, and imipenem.
1. Introduction
+e genus Campylobacter includes small, motile, and curved
Gram-negative bacteria [1–3].+ese rod-shaped bacteria are
thermophilic, 30°C to 46°C, and microaerophilic, 5% O2, and
belong to the family Campylobacteraceae [4]. Campylo-
bacter is a zoonotic pathogen that is colonized in the in-
testinal tract of domestic and wild animals and birds and can
infect human through consumption of contaminated water,
different foods such as raw or uncookedmeat, unpasteurized
milk, and contact with infected animals or (rarely) human
[4, 5]. Poultry, cattle, sheep, pigs, birds, dogs, and cats are
common reservoir hosts for human infections [2].+is food-
borne bacterial pathogen is the major cause of bacterial
gastroenteritis and septicemia in humans in both developing
and developed countries [1, 2]. In developed countries,
Campylobacter bacteria are the most important causative
agents for gastrointestinal infection [6]. It is estimated that
between 400 and 500 million individuals become infected
with Campylobacter species in the world annually [4, 5]. +e
most common species associated with bacterial gastroen-
teritis in human are Campylobacter jejuni and Campylo-
bacter coli as well as Campylobacter fetus associated with
systemic infections [2, 4]. Additionally, in some cases, these
enteric pathogens are associated with two immune-related
late complications, i.e., Guillain-Barré syndrome and reac-
tive arthritis [1, 2]. +e severity of Campylobacter infections
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varies from a mild and self-limiting illness to severe in-
fections [5]. For the treatment of self-limiting intestinal
infections, the replacement of fluids and electrolytes is
enough, while severe extraintestinal Campylobacter infec-
tions such as septicemia, endocarditis, and septic throm-
bophlebitis should be treated with appropriate antibiotics
[2, 7]. Macrolides, including erythromycin and azi-
thromycin, and fluoroquinolones are considered as the
drugs of choice for infected patients [2, 4, 5]. Alternative
treatments are tetracyclines and gentamicin [2, 4, 5]. Ad-
ditionally, Campylobacter strains are susceptible to amoxi-
cillin/clavulanic acid, imipenem, aminoglycosides,
chloramphenicol, and clindamycin [2]. However, in recent
years, antimicrobial resistance of Campylobacter species has
been increased in both developing and developed countries
and is becoming a global problem [8]. It is noteworthy that
resistance to penicillins, cephalosporins, and sulfonamides
has emerged [2]. On the other hand, in February 2017, the
World Health Organization (WHO) announced that fluo-
roquinolone-resistant Campylobacter species are growing
globally, calling for a priority to find effective antibiotics [9].
+erefore, the aim of the present systematic review and
meta-analysis was to evaluate the antimicrobial suscepti-
bility patterns of Campylobacter species, especially fluo-
roquinolone-resistant strains, isolated from human and
animal origins in Iran.
2. Methods
2.1. Literature Search and Selection Criteria. We started at 1
August 2018 for a comprehensive literature search in in-
ternational search engines including PubMed (https://www.
ncbi.nlm.nih.gov), Scopus (https://www.scopus.com), ISI
Web of Knowledge (https://www.isiwebofknowledge.com),
Google Scholar (http://scholar.google.com), and Scientific
Information Database (SID) (http://www.sid.ir), a national
database, on each report about the prevalence of the anti-
microbial susceptibility patterns of Campylobacter species in
Iran. +ere was no date and language limitation for
searching, and related keywords used were antibiotic re-
sistance, Campylobacter species (C. jejuni, C. coli, and
C. lari), and Iran. A number of missed studies were obtained
by reviewing the list of references and searching for journals.
+e meta-analysis was performed step by step based on the
PRISMA recommendations [10].
Inclusion or exclusion criteria for assessing eligibility in
the study were all types of Persian- and English-language
articles which had enough data on the prevalence of the
resistance patterns of campylobacters, in species level, to
different antibiotics in Iran. Review articles, case reports,
abstracts of articles, and duplicates were excluded. Articles
evaluating the resistance patterns of campylobacters only at
the genus level or the resistance genes and those studies with
unclear results were excluded.
2.2. Data Extraction of Articles. After completely reviewing
all included studies by two authors, needed information was
extracted and placed in Tables 1–3 based on organism
species type. +e quality of data was evaluated based on the
Newcastle-Ottawa scale adapted for cross-sectional studies
(data has not been shown). +e checklist of items was based
on three criteria including selection (representativeness of
the sample, sample size, nonrespondents, and ascertainment
of the exposure) (maximum 5 stars), comparability (com-
parability of outcome groups) (maximum 2 stars), and
outcome (assessment of the outcome and statistical test)
(maximum 3 stars).
Data obtained from eligible studies include publishing
year, location of the study, number of strains, origin of
samples, methods used for antimicrobial susceptibility
testing, and antibiotic resistance profiles of C. jejuni, C. coli,
and C. lari.
2.3. Meta-Analysis. +e data for the quantitative data syn-
thesis were transferred to the Comprehensive Meta-Analysis
(CMA) software (Biostat, Englewood, NJ). Resistance rates
of C. jejuni, C. coli, and C. lari were calculated for each
antibiotic as a percentage and expressed as 95% confidence
intervals (95% CIs). I2 statistic was used to evaluate the
existed heterogeneity, and considering the percent of in-
consistency among studies, pooling of data was performed
using fixed-or random-effects models. +e assessment of
publication bias was done using funnel plots.
3. Results
3.1.Characteristics of IncludedStudies. As shown in Figure 1,
a total of 1299 articles were obtained from five databases
(PubMed, Scopus, ISI Web of Knowledge, Google Scholar,
and SID). According to the presented inclusion or exclusion
criteria in Figure 1, 1249 articles were removed and the
eligibility of 50 remained articles was evaluated. Among
them, 16 studies did not meet inclusion criteria because of
reporting the resistance patterns of campylobacters only in
the genus level or had inadequate information, while 34
articles (9 in Persian and 25 in English) had complete data
and were included in our meta-analysis.
+e characteristics of the 34 included studies are sum-
marized in Tables 1–3. +e main data was extracted from 3
studies from Ahvaz [11–13], 2 studies from Hamadan
[14, 15], 4 studies from Isfahan [16–19], 1 study from
Kerman [20], 1 study from Kurdistan [21], 2 studies from
Mashhad [22, 23], 1 study from Mazandaran and Golestan
[24], 1 study from Rafsanjan [25], 5 studies from Shahrekord
[13, 18, 26–28], 2 studies from Semnan [29, 30], 4 studies
from Shiraz [31–34], 8 studies from Tehran [35–42], 2
studies from Tonekabon [34, 43], 1 study from Yazd [19],
and 1 study from Zahedan [44]. Disk diffusion, E-test, and
agar dilution were the most common methods used to
evaluate antibiotic-resistant Campylobacter species in Iran
(Tables 1–3). Additionally, the most common Campylo-
bacter species for which their antibiotic resistance has been
evaluated were C. jejuni, C. coli, and C. lari. +e origins of
Campylobacter species were human and animal fecal sam-
ples as well as food samples with animal origin including
milk, dairy products, and animal meats like poultry, cattle,
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sheep, camels, beef, water buffalo, ducks, and geese. A
random-effects model was used for pooling data on the
prevalence of antibiotic resistance of Campylobacter species
due to the presence of high heterogeneity (I2> 25%). +ere
was some evidence of publication bias (Figures 2 and 3).
3.2. Characteristics of C. jejuni Antibiotic Resistance. In our
presented meta-analysis, a total of 34 studies determined the
prevalence of C. jejuni antibiotic resistance (Table 1). An-
timicrobial resistance patterns of C. jejuni in Iran were as
follows: 22.8% (95% CI: 15.9–31.6) to ampicillin, 17.7% (95%
CI: 11.4–26.5) to amoxicillin, 25.8% (95% CI: 14.5–41.7) to
colistin, 24.3% (95% CI: 16.8–33.7) to enrofloxacin, 2.3%
(95% CI: 0.8–6.4) to spectinomycin, 8.6% (95% CI: 3.9–17.7)
to neomycin, 7.1% (95% CI: 4.7–10.7) to streptomycin, 6%
(95% CI: 4.1–8.6) to chloramphenicol, 50.7% (95% CI:
41.1–60.4) to tetracycline, 66.9% (95% CI: 40.5–85.8) to
trimethoprim/sulfamethoxazole, 41.2% (95% CI: 25.1–59.5)
to cefotaxime, 6.4% (95% CI: 3.6–11.1) to erythromycin,
53.6% (95% CI: 43.9–62.9) to ciprofloxacin (Figure 4), 0% to
imipenem, 4.5% (95% CI: 2.5–7.7) to gentamicin, 9.5% (95%
CI: 0.6–65.5) to meropenem, 89.4% (95% CI: 73.8–96.2) to
cephalothin, 59.6% (95% CI: 52.1–66.7) to nalidixic acid,
54.6% (95% CI: 38.9–69.4) to ceftazidime and 76.5% (95%
CI: 54.5–89.8) to cephalexin. Additionally, other antibiotic
resistance patterns were as follows: clindamycin 4 (66.6%),
tylosin 15 (31.2%), oxacillin 9 (100%), amikacin 4 (5.1%),
azithromycin 0 (0%), ceftriaxone 9 (56.2%), amoxi-clave 16
(100%), penicillin 16 (100%), vancomycin 16 (100%),
tobramycin 4 (25%), ofloxacin 55 (87.3%), and carbenicillin
25 (39.6%).
3.3. Characteristics of C. coli Antibiotic Resistance. +e
characteristics of the 29 studies that determined the prev-
alence of C. coli antibiotic resistance are summarized in
Table 2. +e prevalence of resistance of C. coli to different
antibiotics was as follows: 24.5% (95% CI: 14.5–38.4) to
ampicillin, 23.5% (95% CI: 13.7–37.2) to amoxicillin, 23.1%
(95% CI: 12.1–39.5) to colistin, 25.1% (95% CI: 19.2–32.1) to
enrofloxacin, 5.4% (95% CI: 2–13.5) to spectinomycin, 8.3%
(95% CI: 4.7–14.1) to neomycin, 11.6% (95% CI: 5.4–23.3) to
streptomycin, 9.6% (95% CI: 4.9–17.8) to chloramphenicol,
47.7% (95% CI: 35.6–60.1) to tetracycline, 67.2% (95% CI:
33.6–89.3) to trimethoprim/sulfamethoxazole, 51.5% (95%
CI: 35.8–66.9) to cefotaxime, 13% (95% CI: 6.9–23) to
erythromycin, 41.8% (95% CI: 31.4–53.1) to ciprofloxacin
(Figure 5), 0% to imipenem, 6.8% (95% CI: 4.3–10.5) to
gentamicin, 27.2% (95% CI: 1.2–92.2) to meropenem, 65.5%
(95% CI: 50.1–78.2) to cephalothin, 49.2% (95% CI:
36.6–61.9) to nalidixic acid, 62.2% (95% CI: 31.8–85.2) to
ceftazidime, and 73% (95% CI: 38.6–92.1) to cephalexin.
Additionally, other antibiotic resistance patterns were as
follows: clindamycin 2 (66.6%), tylosin 2 (11.7%), oxacillin 5
(100%), amikacin 3 (7.3%), ceftriaxone 9 (100%), amoxi-
clave 9 (100%), penicillin 9 (100%), vancomycin 9 (100%),
tobramycin 0 (0%), ofloxacin 11 (64.7%), and carbenicillin 7
(41.1%).
3.4.CharacteristicsofC. lariAntibioticResistance. A total of 4
studies investigating the prevalence of C. lari antibiotic
resistance were included in the meta-analysis (Table 3).
Antimicrobial resistance patterns of C. lari in Iran were as
follows: 60% (95%CI: 19–90.5) to ampicillin, 93.7% (95%CI:
46.1–99.6) to amoxicillin, 14.3% (95% CI: 2–58.1) to
streptomycin, 20.9% (95% CI: 10.8–36.7) to chloramphen-
icol, 10.5% (95% CI: 4–24.9) to tetracycline, 16.7% (95% CI:
4.2–47.7) to trimethoprim/sulfamethoxazole, 70.4% (95%
CI: 51.3–84.3) to cefotaxime, 7.4% (95% CI: 2.4–20.6) to
erythromycin, 0% to ciprofloxacin, 12.7% (95% CI: 5.1–28.5)
to gentamicin, and 63.2% (95% CI: 32.7–85.9) to cephalexin.
1299 articles identified through PubMed, scopus,
ISI web of knowledge, google scholar, and SID
1249 articles screened aer title and abstract 
reviewing
Id
en
tifi
ca
tio
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
clu
de
d
50 full text of articles evaluated for eligibility
34 articles included in the meta-analysis
Inclusion criteria:
1. Published paper in Persian
and English languages
2. e prevalence of drug
resistance of 
Campylobacter species in
Iran
3. Cross-sectional and cohort
studies
Exclusion criteria:
1. Duplicates
2. Abstracts list of congresses
3. Letters, case reports, and
reviews
4. Inadequate and unclear
data
Figure 1: A summary of the study selection processes.
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Additionally, other antibiotic resistance patterns were as
follows: ceftriaxone 7 (100%), amikacin 0 (0%), amoxi-clave
7 (100%), penicillin 7 (100%), vancomycin 7 (100%) and
tobramycin 2 (29%).
Abbreviations: AMP: ampicillin; AMX: amoxicillin;
CST: colistin; NFX: enrofloxacin; SPT: spectinomycin; NEO:
neomycin; STR: streptomycin; CHL: chloramphenicol; TET:
tetracycline; TMP/SMX: trimethoprim/sulfamethoxazole;
CTX: cefotaxime; ERY: erythromycin; CIP: ciprofloxacin;
IPM: imipenem; GEN: gentamicin; MEM:meropenem; CEF:
cephalothin; NAL: nalidixic acid; CAZ: ceftazidime; LEX:
cephalexin; AST: antimicrobial susceptibility testing; ND:
not determined.
4. Discussion
Food-borne illnesses caused by Campylobacter species as
well as other bacteria related to food poisoning can be
Event 
rate
Lower 
limit
Upper 
limit Z-value p-value Total
–1.00 –0.50 0.00 0.50 1.00
Ahvaz-1 0.672 0.600 0.737 4.488 0.000 119 / 177
Ahvaz-2 0.444 0.177 0.749 –0.333 0.739 4 / 9
Ahvaz-Shahrekord 0.292 0.146 0.498 –1.976 0.048 7 / 24
Hamadan-1 0.283 0.178 0.418 –3.048 0.002 15 / 53
Hamadan-2 0.929 0.423 0.996 1.748 0.081 6 / 6
Isfahan-1 0.727 0.511 0.872 2.049 0.040 16 / 22
Isfahan-2 0.692 0.409 0.880 1.349 0.177 9 / 13
Isfahan-Shahrekord 0.300 0.100 0.624 –1.228 0.220 3 / 10
Isfahan-Yazd 0.500 0.353 0.647 0.000 1.000 21 / 42
Kurdistan 0.620 0.480 0.743 1.680 0.093 31 / 50
Mashhad-1 0.840 0.782 0.885 8.597 0.000 168 / 200
Mashhad-2 0.877 0.806 0.925 7.126 0.000 107 / 122
Mazandaran-Golestan 0.797 0.695 0.872 4.896 0.000 63 / 79
Rafsanjan 0.025 0.002 0.298 –2.558 0.011 0 / 19
Shahrekord-1 0.500 0.059 0.941 0.000 1.000 1 / 2
Shahrekord-2 0.517 0.443 0.591 0.457 0.647 89 / 172
Shahrekord-3 0.657 0.488 0.794 1.827 0.068 23 / 35
Semnan-1 0.148 0.057 0.335 –3.229 0.001 4 / 27
Semnan-2 0.132 0.056 0.280 –3.932 0.000 5 / 38
Shiraz-1 0.938 0.461 0.996 1.854 0.064 7 / 7
Shiraz-2 0.625 0.482 0.749 1.713 0.087 30 / 48
Shiraz-3 0.031 0.002 0.350 –2.390 0.017 0 / 15
Shiraz-4 0.031 0.002 0.350 –2.390 0.017 0 / 15
Tehran-1 0.516 0.415 0.616 0.311 0.756 48 / 93
Tehran-2 0.111 0.015 0.500 –1.961 0.050 1 / 9
Tehran-3 0.842 0.608 0.948 2.661 0.008 16 / 19
Tehran-4 0.855 0.786 0.905 7.340 0.000 118 / 138
Tehran-5 0.853 0.692 0.937 3.630 0.000 29 / 34
Tehran-6 0.486 0.371 0.601 –0.239 0.811 34 / 70
Tehran-7 0.586 0.404 0.748 0.924 0.356 17 / 29
Tonekabon-1 0.038 0.002 0.403 –2.232 0.026 0 / 12
Tonekabon-2 0.029 0.002 0.336 –2.436 0.015 0 / 16
0.536 0.439 0.629 0.724 0.469
Study name Statistics for each study Event rate and 95% CI
Figure 2: Funnel plot of the meta-analysis of the prevalence of C. jejuni resistant to ciprofloxacin in Iran.
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Figure 3: Funnel plot of the meta-analysis of the prevalence of C. coli resistant to ciprofloxacin in Iran.
Event 
rate
Lower 
limit
Upper 
limit Z-value p-value Total
–1.00 –0.50 0.00 0.50 1.00
Ahvaz-1 0.190 0.073 0.412 –2.604 0.009 4 / 21
Ahvaz-2 0.200 0.027 0.691 –1.240 0.215 1 / 5
Ahvaz-Shahrekord 0.429 0.144 0.770 –0.377 0.706 3 / 7
Hamadan-1 0.368 0.187 0.597 –1.133 0.257 7 / 19
Hamadan-2 0.667 0.154 0.957 0.566 0.571 2 / 3
Isfahan-1 0.071 0.004 0.577 –1.748 0.081 0 / 6
Isfahan-2 0.250 0.034 0.762 –0.951 0.341 1 / 4
Isfahan-Shahrekord 0.333 0.043 0.846 –0.566 0.571 1 / 3
Isfahan-Yazd 0.250 0.063 0.623 –1.346 0.178 2 / 8
Kurdistan 0.750 0.377 0.937 1.346 0.178 6 / 8
Mashhad-1 0.444 0.272 0.631 –0.576 0.565 12 / 27
Mashhad-2 0.556 0.369 0.728 0.576 0.565 15 / 27
Mazandaran-Golestan 0.878 0.739 0.948 4.136 0.000 36 / 41
Rafsanjan 0.038 0.002 0.403 –2.232 0.026 0 / 12
Shahrekord-1 0.385 0.170 0.656 –0.824 0.410 5 / 13
Shahrekord-2 0.267 0.104 0.533 –1.733 0.083 4 / 15
Shahrekord-3 0.100 0.006 0.674 –1.474 0.140 0 / 4
Shiraz-1 0.824 0.573 0.942 2.421 0.015 14 / 17
Shiraz-2 0.045 0.003 0.448 –2.103 0.035 0 / 10
Shiraz-3 0.045 0.003 0.448 –2.103 0.035 0 / 10
Tehran-1 0.464 0.292 0.646 –0.378 0.706 13 / 28
Tehran-2 0.872 0.727 0.946 4.002 0.000 34 / 39
Tehran-3 0.303 0.171 0.477 –2.199 0.028 10 / 33
Tehran-4 0.652 0.443 0.816 1.436 0.151 15 / 23
Tehran-5 0.500 0.244 0.756 0.000 1.000 6 / 12
Tehran-6 0.409 0.228 0.618 –0.848 0.396 9 / 22
Tehran-7 0.800 0.309 0.973 1.240 0.215 4 / 5
Tonekabon-1 0.056 0.003 0.505 –1.947 0.052 0 / 8
Tonekabon-2 0.050 0.003 0.475 –2.029 0.042 0 / 9
0.418 0.314 0.531 –1.431 0.152
Study name Statistics for each studyy Event rate and 95% CI
Figure 4: Forest plot of the meta-analysis of the prevalence of C. jejuni resistant to ciprofloxacin in Iran.
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prevented by avoiding food contamination and growth of
bacteria through proper food preparation and proper
cooking as well as avoidance of contamination of water
sources and consuming pasteurized dairy products [2, 45].
However, the main problem is food contamination with
drug-resistant pathogens, which is a major threat to public
health [46]. Antibiotic resistance genes can be transferred
among food-borne pathogens, and this makes the treatment
of severe infections difficult [46]. Today, fluoroquinolone-
resistant Campylobacter species have turned into a global
concern [9]. Fluoroquinolones are selective drugs in the
treatment of campylobacteriosis; however, an increasing
trend of resistance in Campylobacter species isolated from
human and animal origins has been reported in the USA and
Canada (19–47%), European countries (17–99%), and Africa
and Asia (>80%) [5]. According to the present study, the
resistance of Campylobacter species isolated from human
and animal origins to quinolones and fluoroquinolones
including ciprofloxacin, nalidixic acid, enrofloxacin, and
ofloxacin was also prevalent in Iran and varied from 0% to
87.3% (Tables 1–3). Efflux pumps, CmeABC, and single
point mutations in DNA gyrase A (GyrA) such as C257T
mutation, the most frequent mutation, are involved in
chromosomally mediated quinolone resistance in Cam-
pylobacter species [5].
Macrolides are also recommended as another selective
antibiotic class for the treatment of campylobacteriosis
[2, 5]. +e resistance rate to erythromycin in Campylobacter
species isolated from human and animal samples in Iran was
low (6.4%, 13%, and 7.4% for C. jejuni, C. coli, and C. lari,
respectively). +e frequency of erythromycin resistance in
Iran was higher than that in Turkey [47], Ethiopia [48],
Canada [49], Australia [50], and the Czech Republic [51] and
lower than that of South Africa [52], Malaysia [53], Italy
[54], and China [55].+e target modifications through point
mutations in the 23S rRNA gene such as A2074C, A2074G,
and A2075G mutations, modifying L4 and L22 ribosomal
proteins along with CmeABC efflux pump, are three main
mechanisms complicated in macrolide resistance in Cam-
pylobacter species [5].
Tetracyclines and gentamicin have also importance in
Campylobacter infection therapy as second-line antibiotics
[2, 4, 5]. +e tet(O) gene, which encodes a ribosomal pro-
tection protein, and CmeABC multidrug efflux pump are
associated with tetracycline resistance in Campylobacter
species [5]. Additionally, aminoglycoside-modifying en-
zymes play an important role in aminoglycoside resistance
in Campylobacter species [5]. Based on the results of this
study, C. jejuni and C. coli antibiotic resistance rates to
tetracycline were much higher than gentamicin. Similar
results were observed in the studies reported from Turkey
[47], Italy [54], South Korea [56], and Poland [57]. More-
over, similar to our results, high rates of tetracycline re-
sistance were reported in the studies of Turkey [47], Canada
[49], South Africa [52], Malaysia [53], Italy [54], China [55],
South Korea [56], and Poland [57]. Noteworthy, the de-
termination of Campylobacter species susceptibility patterns
against other antibiotics has received less attention. One
reason could be attributed to the high sensitivity of bacteria
to these antibiotics. For example, in the current study,
antibiotic resistance pattern to protein synthesis inhibitors
was low. On the other hand, resistance to protein synthesis
inhibitors was lower than cell growth inhibitors and folic
acid metabolism inhibitors.
As shown in other studies, the efficacy of cell growth
inhibitor antibiotics against Campylobacter species is limited
[5]. Our study also showed that among the three evaluated
Campylobacter species, antibiotic resistance to β-lactam
antibiotics, especially penicillins and cephalosporins, was
high. On the other hand, the resistance rate to imipenemwas
lower than meropenem. +e intrinsic resistance and
β-lactamase enzymes are twomainmechanisms of resistance
to β-lactam antibiotics in Campylobacter species [5]. +e
intrinsic resistance is also the main resistance mechanism of
Campylobacter species against vancomycin and folic acid
metabolism inhibitors [5]. Our results confirmed high re-
sistance rates to these antibiotics probably due to intrinsic
resistance.
5. Conclusion
In accordance with the WHO report on fluoroquinolone-
resistant Campylobacter species in the world and the urgent
need to develop new antibiotics, our meta-analysis showed a
high prevalence of resistance of Campylobacter species
isolated from human and animal origins to quinolones and
fluoroquinolones in Iran. On the other hand, compared to
penicillins, cephalosporins, and sulfonamides,
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Figure 5: Forest plot of the meta-analysis of the prevalence of C. coli resistant to ciprofloxacin in Iran.
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Campylobacter species were susceptible or showed low re-
sistance rates to aminoglycosides, chloramphenicol, and
imipenem. +erefore, these antibiotics could be recom-
mended for the treatment of campylobacteriosis in Iran. We
recommend monitoring antibiotic-resistant Campylobacter
species through continuous drug sensitivity monitoring and
investigating resistance mechanisms, especially against flu-
oroquinolones, to prevent further expansion of resistant
species in Iran.
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